Britain's medicines regulator approved the Wegovy pill on June 11, the first GLP-1 weight-loss tablet cleared by any regulator in Europe. The drug is oral semaglutide, the same molecule inside Novo Nordisk's weekly Wegovy injection, reformulated into a once-daily 25 mg tablet for adults with obesity.
The Medicines and Healthcare products Regulatory Agency, the UK's equivalent of the FDA, licensed the tablet ↗ for adults with a body mass index of 30 or higher, or 27 and above with a weight-related condition such as type 2 diabetes or high blood pressure. That is the same population the injection already serves. What changes is the delivery: a pill instead of a needle.
Approval is not access. The tablet is not on the National Health Service. Patients who want it now have to pay privately, and public coverage waits on a separate cost-effectiveness review by the National Institute for Health and Care Excellence (NICE), the body that decides what the NHS will pay for. So the headline, first GLP-1 pill approved in Europe, and the reality, that most British patients still cannot get it on the public system, sit a long way apart.
The number behind the approval depends on how you count. In OASIS 4, the 64-week trial of 307 adults the dossier rests on, patients on the 25 mg tablet lost about 13.6 percent of their body weight versus roughly 2 percent on placebo, measured across everyone enrolled regardless of whether they stayed on the drug. Measured only in the patients who stuck with it, the OASIS 4 results ↗ put the figure at 16.6 percent. That second number is the one the European Medicines Agency's scientific committee cited when it recommended the pill in May. Same trial, two honest ways to report it, a three-point gap between them.
Dosing is a slow climb. Patients start at 1.5 mg daily and step up through 4 mg and 9 mg to 25 mg, a month at each rung, to blunt the nausea that comes with starting any GLP-1. Anyone already on the 2.4 mg weekly injection can switch straight to the 25 mg tablet.
Semaglutide ↗ is the most-covered molecule on this platform, and the pill does not change its biology. It still mimics the gut hormone GLP-1 to dampen appetite and prompt insulin release. The question the UK approval sharpens is commercial, not pharmacological: whether an oral version widens who actually takes the drug, or whether the price and the NICE bottleneck keep the pill a private-clinic product while the injection stays the default. Novo has now licensed the tablet in three countries, the US in January, the UAE on June 3, and the UK this week. The European mainland is next.